BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/28/2020 1:45:46 AM | Browse: 650 | Download: 1037
 |
Received |
|
2020-05-26 22:26 |
|
Peer-Review Started |
|
2020-05-26 22:28 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-06-15 17:40 |
|
Revised |
|
2020-08-20 17:37 |
|
Second Decision |
|
2020-09-07 10:15 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2020-09-08 00:50 |
|
Articles in Press |
|
2020-09-08 00:50 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2020-09-14 11:13 |
|
Publish the Manuscript Online |
|
2020-09-28 01:45 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Infectious Diseases |
| Manuscript Type |
Opinion Review |
| Article Title |
Role of monoclonal antibody drugs in the treatment of COVID-19
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Claudio Ucciferri, Jacopo Vecchiet and Katia Falasca |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Katia Falasca, MD, PhD, Associate Professor, Clinic of Infectious Diseases, Department of Medicine and Science of Aging, University “G. d’Annunzio” Chieti-Pescara, Via dei Vestini, Chieti 66100, Italy. k.falasca@unich.it |
| Key Words |
Tocilizumab; Anakinra; Canakinumab; Ruxolitinib; Clazakizumab; Siltuximab |
| Core Tip |
Elevated inflammatory cytokines have been reported in patients with coronavirus disease 2019 (COVID-19). Evidence suggests that elevated cytokine levels and high levels in inflammatory markers are responsible for multi-organ damage in patients with COVID 19. Numerous randomized clinical trials are currently underway to explore the effectiveness of interleukin-1 blockers, interleukin-6 inhibitors. Or other strategies. For this reason it is necessary to make the point about using biopharmaceutical drugs in COVID 19. |
| Publish Date |
2020-09-28 01:45 |
| Citation |
Ucciferri C, Vecchiet J, Falasca K. Role of monoclonal antibody drugs in the treatment of COVID-19. World J Clin Cases 2020; 8(19): 4280-4285 |
| URL |
https://www.wjgnet.com/2307-8960/full/v8/i19/4280.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v8.i19.4280 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
